Follow
Lærke Smidt Gasbjerg
Lærke Smidt Gasbjerg
Verified email at sund.ku.dk
Title
Cited by
Cited by
Year
Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice
H Kissow, B Hartmann, JJ Holst, NE Viby, LS Hansen, MM Rosenkilde, ...
Regulatory peptides 179 (1-3), 91-100, 2012
922012
Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals
LS Gasbjerg, MM Helsted, B Hartmann, MH Jensen, MBN Gabe, ...
Diabetes 68 (5), 906-917, 2019
862019
The gluco-and liporegulatory and vasodilatory effects of glucose-dependent insulinotropic polypeptide (GIP) are abolished by an antagonist of the human GIP receptor
M Asmar, A Asmar, L Simonsen, LS Gasbjerg, AH Sparre-Ulrich, ...
Diabetes 66 (9), 2363-2371, 2017
752017
Biased and constitutive signaling in the CC-chemokine receptor CCR5 by manipulating the interface between transmembrane helices 6 and 7
A Steen, S Thiele, D Guo, LS Hansen, TM Frimurer, MM Rosenkilde
Journal of Biological Chemistry 288 (18), 12511-12521, 2013
712013
GIP (3-30) NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study
LS Gasbjerg, MB Christensen, B Hartmann, AR Lanng, AH Sparre-Ulrich, ...
Diabetologia 61 (2), 413-423, 2018
682018
Species‐specific action of (Pro3) GIP–A full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors
AH Sparre‐Ulrich, LS Hansen, B Svendsen, M Christensen, FK Knop, ...
British journal of pharmacology 173 (1), 27-38, 2016
682016
N‐terminally and C‐terminally truncated forms of glucose‐dependent insulinotropic polypeptide are high‐affinity competitive antagonists of the human GIP receptor
LS Hansen, AH Sparre‐Ulrich, M Christensen, FK Knop, B Hartmann, ...
British journal of pharmacology 173 (5), 826-838, 2016
662016
Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study
NC Bergmann, A Lund, LS Gasbjerg, ECE Meessen, MM Andersen, ...
Diabetologia 62 (4), 665-675, 2019
602019
Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents
LS Gasbjerg, MBN Gabe, B Hartmann, MB Christensen, FK Knop, JJ Holst, ...
Peptides 100, 173-181, 2018
582018
Human GIP (3-30) NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not …
MBN Gabe, AH Sparre-Ulrich, MF Pedersen, LS Gasbjerg, A Inoue, ...
Biochemical pharmacology 150, 97-107, 2018
532018
GIP (3–30) NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release
AH Sparre-Ulrich, MN Gabe, LS Gasbjerg, CB Christiansen, B Svendsen, ...
Biochemical pharmacology 131, 78-88, 2017
532017
Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
LS Gasbjerg, NC Bergmann, S Stensen, MB Christensen, MM Rosenkilde, ...
Peptides 125, 170183, 2020
422020
Effect of intracoronary and intravenous melatonin on myocardial salvage index in patients with ST-elevation myocardial infarction: a randomized placebo controlled trial
S Ekeloef, N Halladin, S Fonnes, SE Jensen, T Zaremba, J Rosenberg, ...
Journal of Cardiovascular Translational Research 10 (5), 470-479, 2017
332017
GLP-2 and GIP exert separate effects on bone turnover: a randomized, placebo-controlled, crossover study in healthy young men
K Skov-Jeppesen, MS Svane, C Martinussen, MBN Gabe, LS Gasbjerg, ...
Bone 125, 178-185, 2019
312019
Separate and combined effects of GIP and GLP-1 infusions on bone metabolism in overweight men without diabetes
NC Bergmann, A Lund, LS Gasbjerg, NR Jørgensen, L Jessen, ...
The Journal of Clinical Endocrinology & Metabolism 104 (7), 2953-2960, 2019
302019
The bile acid‐sequestering resin sevelamer eliminates the acute GLP‐1 stimulatory effect of endogenously released bile acids in patients with type 2 diabetes
A Brønden, A Albér, U Rohde, LS Gasbjerg, JF Rehfeld, JJ Holst, ...
Diabetes, Obesity and Metabolism 20 (2), 362-369, 2018
292018
Circulating glucagon 1-61 regulates blood glucose by increasing insulin secretion and hepatic glucose production
NJW Albrechtsen, RE Kuhre, D Hornburg, CZ Jensen, M Hornum, ...
Cell reports 21 (6), 1452-1460, 2017
242017
Extracellular disulfide bridges serve different purposes in two homologous chemokine receptors, CCR1 and CCR5
PC Rummel, S Thiele, LS Hansen, TP Petersen, AH Sparre-Ulrich, ...
Molecular Pharmacology 84 (3), 335-345, 2013
242013
GIP and GLP-1 receptor antagonism during a meal in healthy individuals
LS Gasbjerg, MM Helsted, B Hartmann, AH Sparre-Ulrich, S Veedfald, ...
The Journal of Clinical Endocrinology & Metabolism 105 (3), e725-e738, 2020
222020
No acute effects of exogenous glucose-dependent insulinotropic polypeptide on energy intake, appetite, or energy expenditure when added to treatment with a long-acting glucagon …
NC Bergmann, LS Gasbjerg, SM Heimbürger, LSL Krogh, F Dela, ...
Diabetes Care 43 (3), 588-596, 2020
192020
The system can't perform the operation now. Try again later.
Articles 1–20